On March 24, 2025, Biogen Inc. announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, Massachusetts. This move is part of a multi-year real estate consolidation strategy aimed at centralizing Biogen’s presence in Kendall Square.
The new state-of-the-art facility, scheduled to open in 2028 to coincide with Biogen's 50th anniversary, will integrate the company’s research and development, technical operations, and global and North American commercial organizations into a co-located innovation hub. Biogen has signed a 15-year lease for approximately 580,000 square feet of office and research and development space.
This strategic investment is designed to foster increased collaboration among employees and external partners, supporting the advancement of Biogen's pipeline of breakthrough medicines. The facility will feature modern laboratories, upgraded workspaces, and sustainable design elements, along with the Biogen CoLab, a community laboratory and collaborative space for talent generation in life science and healthcare.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.